Back to Authors

Iommazzo, Dana

A5004751222

Mayo Clinic

Novartis Pharmaceuticals Corporation, East Hanover, NJ;

Citations 1

ReTHINK: A randomized, double-blind, placebo-controlled, multicenter, phase 3 study of ruxolitinib in early myelofibrosis patients.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS7080-TPS7080

10.1200/jco.2016.34.15_suppl.tps7080